Aidar Health

Creating a new paradigm for personalized care at home.

We are reimagining today’s standards for disease management, and digital medicine, and enabling aging in place.

Empowering personalized care

Aidar Health designs and develops clinically validated software and breath- and saliva-based biosensors, to deliver evidence-based digital interventions for various diseases in therapeutic areas such as respiratory, renal, infectious, cardiovascular, and oncology.

Our Products

We are building towards a new vision of connected health and social care. Our proprietary device, technology, and platform provide actionable data and key health insights geared toward precision medicine.

Aidar Connect^TM

Clinicians Web Application

We offer a clinical decision support platform augmented by data science technology to create a new kind of personalized experience for both patients and providers.

MouthLab^TM

Medical Device

We offer an FDA-cleared, cellular-enabled, hand-held, non-invasive rapid health assessment device that measures 10+ medical parameters in 60 seconds.

Aidar Care^TM

Patients Mobile Application

We offer a personalized mobile app to engage, educate, and empower patients and their caregivers.
‍

Our Goal

Aidar aims to develop and deliver innovative digital medicine solutions to enable providers, life sciences, and payers
to empower their patients to make sustainable behavior changes for improved outcomes.

Our Services

Aidar aims to provide improved health outcomes for users through precision medicine, smarter engagement and tracking tools for providers and caregivers, drug optimization and treatment validation tools for life sciences, and population health management solutions for payers.

Starter

Health Systems

We help providers transition of care from reactive and largely episodic care that is increasingly costly and inefficient, to care that is proactive, digitally enabled, customized, and delivers better value for patients and caregivers.

Remote Physiological Monitoring (RPM)

Enable direct communication and data sharing amongst all healthcare stakeholders to improve patient adherence , satisfaction, and persistence, and enhance clinical decision-making.

Chronic Care Management (CCM)

Enable physicians and nurses to have real-time access to critical information about their patient's physiological condition and optimize treatment and the delivery of care to enable better health and financial outcomes.

Transitional Care Management (TCM)

Enable providers to risk stratify patients for the detection of early signs of disease progression to predict and prevent an exacerbation and ultimately, reduce 30-day readmission or avoid unnecessary emergency room visits.

Hospital-at-Home (HaH)

Provide unbiased objective, non-invasive assessments of clinical statues outside a hospital setting, and enable personalized approaches to treatment and care.

Need help? Contact support

Clinical Trials

Life Sciences

Aidar combines data from biomarkers (both physical & digital) with predictive algorithms to help life science companies enhance the value of therapies and delivery of precision medicine to the right patient at the right time using the right drug platforms.

Digital Biomarker (DB)

Collect and assess unique digital biomarkers that enable objective and precise clinical trial endpoints to facilitate pharmacovigilance related to specific therapies, applicable across multiple therapeutic areas.

Digital Companion (DC)

Provide MouthLab monitoring system as a digital companion product to complement existing treatments, empower, and connect patients, clinicians, and healthcare systems to improve the quality of care.

Decentralized Clinical Trials (DCT)

Facilitate digital efforts to enhance the feasibility of emerging clinical trial designs (virtual/hybrid) by bringing research to the patient’s homes thus fostering inclusivity, health equity, and diversification of trial participants.

Real-World Evidence (RWE)

Generate real-world evidence on adherence, effectiveness, adverse events, and treatment risks to substantiate post-marketing drug safety commitments and to reassess label extension, pricing, broadened indication and reimbursement across customer segments.

Need help? Contact support